NovaBay Pharmaceuticals (NBY)
(Delayed Data from AMEX)
$0.08 USD
0.00 (2.34%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.08 0.00 (1.52%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth A Momentum B VGM
Balance Sheet
Fiscal Year End for NovaBay Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 3 | 5 | 8 | 12 | 7 |
Receivables | 1 | 2 | 2 | 1 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 3 | 3 | 3 | 1 | 0 |
Other Current Assets | 0 | 1 | 1 | 1 | 1 |
Total Current Assets | 7 | 11 | 13 | 14 | 9 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 3 | 10 | 0 | 0 |
Deposits & Other Assets | 1 | 0 | 0 | 0 | 0 |
Total Assets | 9 | 16 | 24 | 15 | 11 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 1 | 0 | 0 | 0 | 3 |
Accounts Payable | 1 | 1 | 1 | 0 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 3 | 2 | 2 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 4 | 4 | 3 | 3 | 6 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 10 | 0 | 4 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 6 | 6 | 14 | 3 | 10 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 2 | 3 | 1 | 0 | 0 |
Common Stock (Par) | 0 | 1 | 0 | 0 | 0 |
Capital Surplus | 176 | 165 | 151 | 148 | 126 |
Retained Earnings | -175 | -158 | -142 | -136 | -125 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 3 | 11 | 10 | 12 | 1 |
Total Liabilities & Shareholder's Equity | 9 | 16 | 24 | 15 | 11 |
Total Common Equity | 1 | 8 | 9 | 12 | 1 |
Shares Outstanding | 11.20 | 1.80 | 1.20 | 1.20 | 0.80 |
Book Value Per Share | 0.12 | 4.21 | 7.91 | 10.27 | 1.21 |
Fiscal Year End for NovaBay Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 3 | 3 | 4 | 4 |
Receivables | NA | 1 | 1 | 3 | 2 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 3 | 3 | 4 | 4 |
Other Current Assets | NA | 0 | 0 | 1 | 1 |
Total Current Assets | NA | 7 | 8 | 11 | 10 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 3 | 3 | 3 |
Deposits & Other Assets | NA | 1 | 1 | 1 | 0 |
Total Assets | NA | 9 | 13 | 16 | 15 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 1 | 1 | 1 | 0 |
Accounts Payable | NA | 1 | 1 | 1 | 1 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 2 | 2 | 3 | 3 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 4 | 5 | 6 | 4 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 6 | 6 | 7 | 6 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 2 | 2 | 2 | 3 |
Common Stock (Par) | NA | 0 | 0 | 1 | 1 |
Capital Surplus | NA | 176 | 171 | 170 | 165 |
Retained Earnings | NA | -175 | -166 | -164 | -160 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 3 | 7 | 9 | 9 |
Total Liabilities & Shareholder's Equity | NA | 9 | 13 | 16 | 15 |
Total Common Equity | 0 | 1 | 5 | 6 | 6 |
Shares Outstanding | 30.10 | 11.20 | 6.50 | 4.20 | 2.10 |
Book Value Per Share | 0.00 | 0.12 | 0.78 | 1.53 | 2.82 |